Diagnostic confirmation and long-term treatment are different cost episodes
A first specialist review may focus on whether current clinical criteria are met, whether molecular NF1 testing is needed and whether another diagnosis such as Legius syndrome should be considered. Long-term care may later involve ophthalmology, neurology, dermatology, orthopedics, oncology or neuropsychology. Ask for a quote tied to the current problem rather than assuming all possible NF1 services must be purchased at once.
Genetic testing cost depends on what has already been done
If a high-quality molecular report already identifies a pathogenic NF1 variant, repeating testing may add little. Atypical, mosaic or unresolved cases may require deletion/duplication analysis, broader RASopathy testing or expert variant interpretation. Genetic counseling can also be a separate appointment. Sending the complete original laboratory report helps avoid duplicated testing.
Imaging costs depend on tumor burden and the clinical question
Known plexiform neurofibromas may need regional MRI, whole-body MRI or targeted follow-up depending on age, prior imaging and symptoms. Complex lesions may benefit from volumetric assessment. Imaging for suspected malignant transformation is a different pathway from routine surveillance and may include focused MRI and selected metabolic imaging.
Surgery varies widely from minor excision to complex nerve or reconstructive procedures
The cost of removing a small symptomatic cutaneous lesion cannot be compared with surgery for a large plexiform neurofibroma involving a major nerve, skull base, neck, retroperitoneum or another critical structure. Planning may require plastic surgery, neurosurgery, peripheral-nerve surgery, ENT, orthopedics or vascular expertise in addition to anesthesia and inpatient care.
MEK-inhibitor treatment is a longitudinal medication-and-monitoring pathway
Current EU-authorized systemic options for selected symptomatic, inoperable NF1-associated plexiform neurofibromas include selumetinib and mirdametinib. Financial planning must include not only the medicine but also eligibility assessment, baseline examinations, laboratory and organ-specific monitoring, response imaging and management of adverse effects. Exact prescribing criteria and reimbursement or self-pay arrangements must be confirmed with the center and current product information.
Suspected MPNST creates a separate oncology cost pathway
Rapid growth, persistent or nocturnal pain, new neurological deficit or other suspicious change may require urgent evaluation for malignant peripheral nerve sheath tumor. That can involve MRI, PET-based imaging, multidisciplinary sarcoma review, carefully planned biopsy, surgery and pathology. It should not be bundled into a routine stable-NF1 second-opinion estimate.
Neuropsychology, ophthalmology and other surveillance can be clinically relevant
NF1 can involve learning and attention difficulties, optic pathway disease, bone abnormalities, hypertension-related conditions and tumors outside the peripheral nerves. The cost plan should include only the organ-specific assessments justified by age, phenotype and symptoms rather than indiscriminate screening.
A multidisciplinary NF board can reduce fragmented repeat consultations
UKE Hamburg publishes an interdisciplinary NF board and a dedicated NF clinic that coordinates molecular genetics, neuropsychology, tumor measurement and treatment planning. For a complex case, centralized review can be more useful than booking unrelated appointments in several departments without a unified question.
International estimates should follow record review
For planned self-pay care, send the genetic report, imaging and prior treatment history before requesting a quotation. The hospital can then determine whether the first step is remote file review, an outpatient multidisciplinary assessment, new imaging, surgery or a systemic-treatment evaluation.
Send these records before asking for an NF1 estimate
A quote becomes more realistic when the hospital can see exactly what is unresolved.
- Complete NF1 genetic report and prior genetic counseling letter
- Neurology or clinical-genetics summary
- MRI DICOM files and radiology reports for known tumors
- Serial imaging showing growth when available
- Whole-body MRI if previously performed
- Operative and pathology reports
- Current symptoms and functional limitations
- Ophthalmology reports if optic-pathway disease is relevant
- Current medicines and previous MEK-inhibitor history
- Any sarcoma or oncology work-up for a suspicious lesion
- Requested service: diagnosis confirmation, surveillance plan, tumor review, surgery opinion, MEK-inhibitor assessment or suspected MPNST review
Official sources
Last source-reviewed 2026-09-03. Cost procedures and published service fees can change, so confirm current terms directly with the provider before transferring money or booking travel.